Sponsored by:

Duke MMIL designs novel SPECT/CT system for 3D breast imaging

Jul 17, 2007
2007 07 17 14 38 39 706
2007 07 17 14 38 39 706
Image courtesy of Duke University Medical Center Multi-Modality Imaging Lab.

close

Latest in Molecular Imaging
Isotopes1
Telix inks deal to acquire ITM for $1.65B
September 21, 2026
Breast Cancer
FES-PET guides second-line therapy decisions in breast cancer
September 18, 2026
Explore Innovations at EANM 2026
Sponsored
Explore Innovations at EANM 2026
September 16, 2026
Approved Stamp 400
Curium gets FDA approval for Lu-177 injection for GEP-NETs
September 15, 2026
Related Stories
2007 07 17 15 08 50 706
Molecular Imaging
Duke MMIL designs novel SPECT/CT system for 3D breast imaging
2007 07 17 14 32 28 706
Molecular Imaging
Duke MMIL designs novel SPECT/CT system for 3D breast imaging
2007 06 25 10 54 15 706
Molecular Imaging
Studies link Alzheimer's to beta-amyloid and potential for new ligand
Explore Innovations at EANM 2026
Sponsor Content
Explore Innovations at EANM 2026
More in Molecular Imaging
Telix inks deal to acquire ITM for $1.65B
By Erik L. Ridley
The deal would create a combined company with significant radioisotope manufacturing, distribution, and radiopharmaceutical development capabilities.
September 21, 2026
Isotopes1
FES-PET guides second-line therapy decisions in breast cancer
By Will Morton
FES-PET/CT results led to therapeutic management changes in 37.8% of patients.
September 18, 2026
Breast Cancer
MICSI secures FDA clearance for MR-guided PET platform
By AuntMinnie.com staff writers
The platform is cleared across F-18 FDG, amyloid (florbetapir, florbetaben, flutemetamol), and tau (flortaucipir) radiotracers.
September 16, 2026
Micsi
Curium gets FDA approval for Lu-177 injection for GEP-NETs
By AuntMinnie.com staff writers
The radioligand therapy delivers targeted radiation to GEP-NETs by binding to somatostatin receptors expressed on these tumors.
September 15, 2026
Approved Stamp 400
CAIX-targeted PET tracer shows promise in patients with ccRCC
By Will Morton
Ga-68 DPI-4452 PET/CT correctly identified all 23 primary clear cell renal cell carcinoma tumors, achieving 100% sensitivity.
September 14, 2026
Representative Ga-68 DPI-4452 PET/CT images of regional and distant metastases in ccRCC from multiple patients, including regional lymph node (A), bilateral adrenal glands (B), lung (C), and bone (D). For each panel, top row shows fused PET/CT images, middle row shows PET-only images, and bottom row shows unenhanced CT images. Target lesions are highlighted by white arrows on fused/CT images and black arrows on PET images.
FDA clears new PET agent for brain cancer imaging
By AuntMinnie.com staff writers
Gliomas account for approximately 30% of all brain and central nervous system tumors.
September 14, 2026
Aneurysm
Ratio Therapeutics, RayzeBio join forces
By AuntMinnie.com staff writers
The firms will collaborate on a radiopharmaceutical program focused on two cancer targets.
September 9, 2026
Hands Shaking Deal
Coalition launches Cardiac PET Alliance
By AuntMinnie.com staff writers
The coalition represents more than 1,200 cardiologists across 101 cardiovascular group practices in 24 states.
September 9, 2026
Heart Valves Artx Premium
Siemens expands PET detector manufacturing site
By AuntMinnie.com staff writers
The project significantly increases production capacity at its East Tennessee Molecular Imaging Complex.
September 9, 2026
Siemens Pet Manufacturing Center
GEHC submits StarGuide GX digital SPECT/CT for FDA clearance
By AuntMinnie.com staff writers
The system uses dual-sided cadmium zinc telluride (CZT) detector technology for higher volume sensitivity and high-res imaging.
September 8, 2026
Ge Health Care Standard Logo
AtomVie opens new radiopharmaceutical manufacturing facility
By AuntMinnie.com staff writers
The new site increases the firm's manufacturing capacity by more than tenfold.
September 4, 2026
Isotope 400
Juniper secures FDA 'breakthrough' nod for hypoxia PET tracer
By AuntMinnie.com staff writers
JBS-003, licensed from Memorial Sloan Kettering Cancer Center, identifies tumor hypoxia, a marker of radioresistance.
September 3, 2026
Throat Cancer
Page 1 of 635
Next Page